Risk factors
Xilio Therapeutics (XLO) risk factors
Item 1A of every Xilio Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors175 risks103 new14 dropped28 reworded
Xilio is developing masked immuno-oncology candidates, funded into 2027 with $137.5M cash plus recent equity and AbbVie milestone proceeds.
Filed Mar 23, 2026 - FY2024 10-K risk factors86 risks
Xilio is entirely dependent on its clinical-stage pipeline candidates, primarily vilastobart and XTX301, with no commercial products or revenue.
Filed Mar 11, 2025